Dear Colleagues,

The year 2023 marks the 10th anniversary of Biomedicines, a peer-reviewed open access journal in the biomedical field. Thus far, Biomedicines has published more than 2700 papers from more than 17,000 authors. We appreciate each author, reviewer, and academic editor whose support has brought us to where we are today. To celebrate this significant milestone, we aim to publish a Special Issue entitled “10th Anniversary of Biomedicines—Advances in Hepatocellular Carcinoma: From Basic to Clinical Research".

Hepatocellular carcinoma (HCC) is the fifth most commonly occurring cancer and the third leading cause of cancer death globally. HCC typically arises in the setting of chronic liver disease at a rate dependent upon the complex interplay between the host, disease and environmental factors. Next to a chronic hepatitis B or C infection, changes in lifestyle and environmental factors in western countries dramatically increases HCC incidence. Surgery, chemotherapy, and radiofrequency ablation are three conventional treatments, while immunotherapy has achieved dramatic advances in recent years and provides new opportunities to treat HCC. However, HCC has various etiologies and can evade the immune system through multiple mechanisms. Understanding the epidemiological evolution of HCC is crucial in combating the rising incidence and will help to reduce the mortality rates associated with this cancer.

This Special Issue supports new insights into basic and clinical research on HCC. This collection of papers will shed light on the pathophysiology, clinical problems, diagnostic methods, therapeutic approaches and lifestyle adaptations of HCC, as well as on its systemic risk factors. The overall aim of this Special Issue is to raise awareness of the opportunities and challenges in translational HCC research, i.e., to explore possible answers that basic research can provide, and vice versa, to translate basic research questions to human situations. This Special Issue invites all junior and senior researchers and clinicians in the field of HCC, to share their novel findings and new ideas.

Prof. Dr. Ronit Shiri-Sverdlov
Dr. Sabine Baumgartner
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• hepatocellular carcinoma
• pathophysiology
• translational research
• NASH
• lipid metabolism